ERBB2 and neoplasm: In particular, the HER2-E subtype represents approximately 6.6–11.0% of HR+/HER2- tumours; thus, the incorporation of novel drugs in combination with endocrine therapy can improve patient outcomes, especially in HER2-E subtype.